Last reviewed · How we verify
Shanghai Bovax Biotechnology Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Active Comparator: GARDASIL ®9 | Active Comparator: GARDASIL ®9 | phase 3 | Recombinant HPV vaccine | Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58 | Oncology / Immunology / Infectious Disease |
Therapeutic area mix
- Oncology / Immunology / Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Boston Medical Center · 1 shared drug class
- Erasmus Medical Center · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shanghai Bovax Biotechnology Co., Ltd.:
- Shanghai Bovax Biotechnology Co., Ltd. pipeline updates — RSS
- Shanghai Bovax Biotechnology Co., Ltd. pipeline updates — Atom
- Shanghai Bovax Biotechnology Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shanghai Bovax Biotechnology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-bovax-biotechnology-co-ltd. Accessed 2026-05-17.